Ventricular remodeling: The appropriate surrogate end point for cell-based therapy?

Shahab Ghafghazi, Marcin Wysoczynski, Matthew C.L. Keith, Joseph B. Moore, Roberto Bolli

Research output: Contribution to journalArticlepeer-review

Abstract

Prevention and reversal of left ventricular (LV) remodeling in ischemic cardiomyopathy are important therapeutic goals because LV remodeling is directly associated with adverse clinical outcomes. Although imaging parameters of remodeling are surrogate markers for clinical outcomes, the optimal surrogate end points in stem cell trials remain unknown. Meta-analyses show a modest beneficial effect on ejection fraction and LV remodeling when using stem cells. Conclusive evidence for cell-based therapies on LV function and structure requires large phase 3 trials. Here, we will review the literature on the significance of LV remodeling relating to clinical end points and remodeling indices as surrogate outcomes in trial design, and summarize the most important clinical trials on cell-based therapy.

Original languageEnglish (US)
Pages (from-to)126-138
Number of pages13
JournalDialogues in Cardiovascular Medicine
Volume20
Issue number2
StatePublished - Jan 1 2015

Keywords

  • Acute myocardial infarction
  • Ejection fraction
  • Ischemic cardiomyopathy
  • Left ventricular end-diastolic volume
  • Left ventricular end-systolic volume
  • Nonischemic cardiomyopathy
  • Progenitor cell
  • Stem cell
  • Ventricular remodeling

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Ventricular remodeling: The appropriate surrogate end point for cell-based therapy?'. Together they form a unique fingerprint.

Cite this